PharmaTher Holdings Ltd. PHRRF PHRMa Pharmaceutical company focused on developing novel uses and dosage forms of ketamine to treat mental, neurological and pain disorders announced that the United States Patent and Trademark Office (“USPTO”) has granted US Patent No. 11,426,366.
The patent is entitled “Compositions and Methods for Treating Motor Disorders” which includes claims aimed at covering ketamine in the potential treatment of Parkinson’s disease and motor disorders that cause involuntary or uncontrollable movements or actions of the body.
“We are pleased to receive the USPTO patent for ketamine for the treatment of Parkinson’s disease and motor disorders,” said Fabio Chianelli, CEO of PharmaTher. “The US patent strengthens our intellectual property portfolio covering novel uses and delivery modes of ketamine.”
Ketamine treatment for patients with Parkinson’s disease
Parkinson’s disease is a debilitating condition affecting an estimated 1 million people in the United States and 10 million people worldwide.
“We are advancing the clinical development of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease and are seeking FDA approval for approval under regulatory pathway 505(b)(2) with a potential clinical phase -3 study,” Chianelli said.
Recently, PharmaTher announced positive efficacy and safety data from a Phase 1/2 clinical study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia (“LID”) in Parkinson’s Disease via a landmark abstract presentation entitled “Subanesthetic Infusion of Ketamine Produces Long-Term Reduction in Levodopa-Induced Dyskinesia” at the MDS International Congress of Parkinson and movement disorders.
Highlights of the study
“The Phase 1/2 study was an open-label, dose-ranging study evaluating the safety, tolerability, and pharmacokinetics of a low-dose ketamine infusion for the treatment of levodopa-induced dyskinesia in Parkinson’s disease…
